Chronic lymphocytic leukaemia trials in Argentina
6 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Where
- Buenos Aires, Ciudad Autónoma de Buenos Aires, Mar del Plata, Rosario
- Age
- 18 years and over
- People
- 735 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00 - Phase 2Taking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Buenos Aires, Caba, Ciudad Autonoma de Buenos Aires, Córdoba, Mendoza, Rosario
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - Phase 3Taking peopleA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Where
- CABA, Ciudad Autonoma Buenos Aires
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00 - Phase 3Taking peopleA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Where
- CABA, Ciudad Autonoma Buenos Aires, San Miguel de Tucumán
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00 - Phase 3Taking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- CABA, Córdoba, Mendoza, Rosario
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - Phase 3Taking peopleA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Ciudad Autónoma de Buenos Aire, Mar del Plata, Santa Fe
- Age
- 18 years and over
- People
- 737 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00